The latest report by IMARC Group titled, “Dengue Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2027”, finds that the global dengue testing market size reached US$ 522.6 Million in 2021. Dengue testing is a procedure used to examine an individual with signs and symptoms of the dengue virus. The dengue virus, also known as breakbone fever, is a viral infection that spreads with a bite of an infected Aedes aegypti mosquito. The most commonly observed symptoms include joint and muscle pain, high fever, vomiting, abdominal pain, clammy and cold skin, difficulty in breathing, mild bleeding in the nose and gums, fatigue, rashes, pain behind the eyes, and headache. The dengue testing involves enzyme-linked immunosorbent assay (ELISA), dengue lgG/lgM rapid tests, and RT-PCR. It is performed using a blood sample to identify the various serotypes of the dengue virus. In recent years, dengue testing has gained momentum due to the rising prevalence of dengue among the masses.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Dengue Testing Market Trends:
One of the primary factors driving the market is the rising global warming and breeding sites of mosquitos. Other than this, densely populated areas are more prone to diseases due to the low living conditions, poor sanitation and waste management techniques, which have catalyzed the market growth. Besides this, the efficient and accurate diagnosis of dengue helps in clinical trials, pathogenesis, outbreak control, vaccine development, academic research, surveillance activities, case confirmation, and early detection of severe cases, thus positively escalating the demand for dengue testing across the globe. Furthermore, several awareness campaigns organized by the governments of various nations are driving the market growth. Moreover, key players are extensively investing in research and development (R&D) activities to develop economical and highly effective dengue test kits. Other growth-inducing factors include technological advancements in the healthcare industry and rapid urbanization. Looking forward, IMARC Group expects the market value to reach US$ 726.34 Million by 2027, expanding at a CAGR of 5.40% during the forecast period (2022-2027).
- Based on the test type, the market has been segmented into ELISA-based tests, RT-PCR based tests, Dengue IgG/IgM Rapid Test, and others.
- On the basis of the end user the market has been classified into, hospitals, diagnostic centers, and others.
- Region-wise the market has been divided into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has been analyzed, with some of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800